NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Merger financing commitments rose to approximately $820 million, including an additional $500 million placement
- ➤SEC declared the merger registration statement effective; stockholder vote scheduled for December 9, 2026
- ➤Combined company expected to operate as Avere and trade under Nasdaq ticker AVRX
- ➤Cash, equivalents, and marketable securities fell to $8.7 million from $41.8 million
- ➤Third-quarter net loss narrowed to $6.8 million from $8.6 million year over year
Expert Statements
Michael Richman, President and CEO of NextCure
“During the third quarter, we continued to execute on the strategic initiatives associated with our proposed merger with Avere Therapeutics”
Michael Richman, President and CEO of NextCure
“Importantly, total financing commitments supporting the proposed transaction increased to approximately $820 million from a syndicate of leading healthcare-focused and institutional investors.”
Michael Richman, President and CEO of NextCure
“We believe this significant financing commitment reflects strong confidence in Avere's clinical development strategy and the potential of AVR-001, while enhancing the opportunity to create long-term value for NextCure stockholders.”
* Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing * S-4 Declared Effective by SEC; Stockholder Vote Scheduled for December 9, 2026 BALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), today provided a business update and reported financial results for the third quarter ended September 30, 2026.
The Company continues to advance its proposed merger (the “Merger”) with Avere Therapeutics, Inc., a privately held biotechnology company focused on oral therapies for IL-23-driven inflammatory diseases (“Avere”), which is now supported by approximately $820 million of committed financing from a syndicate of leading healthcare-focused and institutional investors. The financing is expected to provide substantial capital to support development of Avere’s lead program, AVR-001, other corporate purposes and the future operations of the combined company following completion of the proposed transaction.
Get started
Create a free account to read the full story.